iBio reached an important clinical milestone during fiscal 2026 as its lead obesity and <a href="https://healthylife7.com/keto-diet-outperforms-others-for-cardiometabolic-health-during-weight-loss-study/” title=”Keto Diet Outperforms Others for Cardiometabolic Health during Weight Loss: Study”>cardiometabolic program IBIO-600 advanced through the single-ascending-dose portion of its first-in-human Phase 1 trial
The company had dosed 31 of the 32 planned participants across all four planned cohorts and reported that no safety findings had been identified that prevented dose escalation
iBio is now preparing to move IBIO-600 into the multiple-ascending-dose escalation portion of the study
The clinical progress marks a significant transition for iBio, which entered fiscal 2026 as a preclinical biotechnology company and ended the year as a clinical-stage developer
IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
The company believes the drug could potentially complement GLP-1 therapies, where preserving lean mass during weight loss has become an important development objective
iBio is simultaneously advancing several other obesity and cardiometabolic programs
IBIO-610, a long-acting Activin E antibody, moved into IND-enabling studies
In obese non-human primates, a single dose produced near-complete suppression of active Activin E for as long as eight weeks, according to the company
Rodent studies also showed fat-selective weight loss, additive body-composition effects when combined with semaglutide and prevention of weight regain after GLP-1 discontinuation
The company also advanced IBIO-800, a myostatin × Activin A bispecific antibody, into IND-enabling development after selecting a development candidate
IBIO-800 is being evaluated for its potential to preserve and increase muscle and address cardiopulmonary disease, initially focusing on pulmonary hypertension associated with heart failure with preserved ejection fraction
Separately, iBio licensed AstralBio’s amylin receptor antibody program, adding several next-generation antibody agonist approaches targeting obesity and metabolic disease
The pipeline expansion was accompanied by substantial financing activity
iBio completed a public offering in August 2025 with potential gross proceeds of up to $100 million if all warrants are exercised for cash
The financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wace and other investors
The company subsequently completed a $26 million private placement in January 2026 led by Frazier Life Sciences and other healthcare-focused institutional investors
At June 30, iBio held approximately $88 million of cash, cash equivalents and investments in debt securities
The company increased R&D spending substantially as those programs advanced
Research and development expense rose to $19.6 million from $8.3 million, primarily reflecting increased spending on IBIO-600, IBIO-610 and other preclinical assets
Fiscal-year net loss widened to $33 million from $18.4 million
Those losses are consistent with iBio’s current status as a clinical-stage biotech without meaningful commercial revenue, making clinical progression and capital re
iBio also strengthened its leadership team by appointing Molly Carr as Chief Medical Officer and adding biotechnology industry veteran Elizabeth Stoner to its board
The positive milestone is the company’s transition into human clinical development while maintaining significant capital to continue advancing a broader obesity and cardiometabolic pipeline
“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“In the last fiscal year, we paired significant scientific progress with disciplined financial execution, substantially strengthening iBio’s balance sheet as we advanced our pipeline into clinical development.”
Felipe Duran, Chief Financial Officer of iBio
